CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
四类暴露/难治性骨髓瘤与生存期短相关
英文原题：Quad-class exposed/refractory myeloma is associated with short survival.
查看英文原题
Quad-class exposed/refractory myeloma is associated with short survival.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
蛋白酶体抑制剂、免疫调节药物、抗CD38单克隆抗体及靶向B细胞成熟抗原（BCMA）的治疗均失败后，复发性多发性骨髓瘤患者的结局数据十分有限；这类患者被称为四类药物暴露/难治（QCE）。本单中心回顾性研究评估45例QCE患者抗BCMA治疗失败后的无进展生存期（PFS）和总生存期（OS）。7例（16%）接受抗体药物偶联物，20例（44%）接受双特异性抗体，18例（40%）接受CAR-T 细胞治疗。30例（67%）接受了1线后续治疗。中位PFS为4.4个月（95% CI 2.4–12.5），中位OS为6.3个月（95% CI 3.9–14.4）。QCE骨髓瘤患者预后不良，仍是未满足的医疗需求。
展开英文摘要原文
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients.
Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received 1 subsequent line of treatment. PFS was 4. 4 months (95% CI = 2. 4-12. 5) and OS 6. 3 months (95% CI = 3. 9-14. 4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
论文信息
- 作者
- Piron B、Costes-Tertrais D、Gastinne T、Fourmont AM、Dubruille V、Blin N、Moreau P、Touzeau C
- 单位
- Department of Hematology, University Hospital, Nantes, France.France
- 期刊
- British journal of haematology2024 Jan
- 原文标识
- PubMed 37833834 · DOI 10.1111/bjh.19148